New hope for immunocompromised patients with severe parainfluenza

NCT ID NCT03808922

Recruiting now Disease control Sponsor: Ansun Biopharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called DAS181 in people with weakened immune systems who have a serious lung infection caused by parainfluenza virus. The goal is to see if the drug helps them breathe without extra oxygen and reduces the risk of death. About 274 participants will receive either DAS181 or a placebo, and the study also includes a smaller group of patients with severe COVID-19.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 immunodeficiency disease lower respiratory tract disorder parainfluenza infectious disease Paramyxoviridae infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 IMMUNOCOMPROMISED LOWER RESPIRATORY TRACT INFECTION PARAINFLUENZA

Contacts and locations

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING

Chicago, Illinois, 60611, United States
Baylor College of Medicine
RECRUITING

Houston, Texas, 77030, United States
Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45267, United States
City of Hope cancer Center
RECRUITING

Duarte, California, 91010, United States
Duke University
RECRUITING

Durham, North Carolina, 27710, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Fred Hutchinson Cancer Research Center
RECRUITING

Seattle, Washington, 98109, United States
Froedtert Medical College Pulmonary Clinic
COMPLETED

Milwaukee, Wisconsin, 53266, United States
MD Anderson
RECRUITING

Houston, Texas, 77030, United States
Mayo Clinic Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
National Cheng Kung University Hospital
TERMINATED

Tainan, Tainan, Taiwan
Oregon Health & Science University
WITHDRAWN

Portland, Oregon, 97239, United States
Samsung Medical Center
TERMINATED

Seoul, Gyeonggi-do, 06351, South Korea
Seattle Children's Hospital
RECRUITING

Seattle, Washington, 98105, United States
Seoul National University Hospital
TERMINATED

Seoul, Gyeonggi-do, 03080, South Korea
Shanghai Pulmonary Hospital
TERMINATED

Yangpu, Shanghai Municipality, 200433, China
The Johns Hopkins Hospital
WITHDRAWN

Baltimore, Maryland, 21205, United States
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of California Davis Health System
RECRUITING

Sacramento, California, 95817, United States
University of Iowa Health Care
RECRUITING

Iowa City, Iowa, 52242, United States
University of Kansas Medical Center
RECRUITING

Fairway, Kansas, 66205, United States
University of Oklahoma Health Sciences Center
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
University of Pittsburgh Medical Center Health System
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States
VCU Health System
RECRUITING

Richmond, Virginia, 23298, United States
Washington University
WITHDRAWN

St Louis, Missouri, 63112, United States
Weill Cornell Medical College
RECRUITING

New York, New York, 10065, United States
Westmead Hospital
TERMINATED

Sydney, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.